Sever’s Disease in a Patient Receiving Growth Hormone with no Causative Relation
Published: March 1, 2018 | DOI: https://doi.org/10.7860/JCDR/2018/30956.11305
Erdal Kurnaz, Senay Savas-Erdeve, Zehra Aycan, Semra Çetinkaya
1. Attending Physician, Paediatric Endocrinology Clinic, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
2. Associate Professor, Paediatric Endocrinology Clinic, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
3. Professor Doctor, Paediatric Endocrinology Clinic, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
4. Professor Doctor, Paediatric Endocrinology Clinic, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
Correspondence
Dr. Erdal Kurnaz,
Attending Physician, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital,
Paediatric Endocrinology Clinic, Altindag/Ankara-06020, Turkey.
E-mail: erdalkurnaz44@gmail.com
Growth Hormone (GH) shows its main effect on bones and muscle tissues. There are reports of orthopaedic complications including carpal tunnel syndrome, Legg-Calve-Perthe’s disease, scoliosis, and slipped capital femoral epiphysis with GH use in the literature, except for calcaneal apophysitis (Sever’s disease). We hereby present the case of a 13-year-old male who was treated with GH for GH deficiency and developed Sever’s disease in the first year of treatment.
[
FULL TEXT ] | [ PDF]